Alzheimer's Disease & Dementia
The burden of Alzheimer disease and related dementias (ADRD) is expected to increase to 3.3% in the United States by 2060.
In this cross-sectional study, the tau marker [18F]flortaucipir accurately distinguished Alzheimer Disease dementia from other non-AD neurodegenerative disorders about 90% of the time.
In this prospective cohort study, older patients with more optimal cardiovascular health metrics had a lower rate of developing dementia in a dose-dependent manner.
Participants with Alzheimer disease have increased levels of 2 strains of human herpesvirus.
While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.
The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.
The use of certain anticholinergic drugs may increase the risk of future dementia.
Using hearing aids may slow cognitive decline in later life.
Researchers concluded that the partnership did not accelerate the overall decline in antipsychotic medication use among study participants.
A study was conducted to assess potential beneficial effects of a lifestyle intervention program on cognition in carriers of the APOE ε4 allele.
In patients with mild Alzheimer's disease, solanezumab did not significantly reduce cognitive decline over time.
Positive beliefs about age may protect against dementia.
Depressive symptoms and apathy were independently associated with incident dementia in community-dwelling older adults.
Increased triglyceride levels at midlife are predictive of the presence of β-amyloid 20 years later in cognitively healthy individuals.
There is a greater risk for cognitive decline and impairment in elderly patients who experience age-related hearing loss.
While there has been increasing understanding of Alzheimer's neuropathology, little is known about the relationship between progression of agitation and disease severity.
The mortality rate from Alzheimer's increased 54.5 percent — from 16.5 per 100,000 people in 1999 to 25.4 per 100,000 in 2014.
More than 81% of participants reported adverse events, but rates were similar between groups.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Minocycline vs Routine Care for Clinical Symptom Improvement in Schizophrenia
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- Mortality Rates in Parkinson Disease Psychosis With Pimavanserin, Quetiapine
- Opioid Overdose Deaths Reach Record Number in United States
- Pathways for Intellectual Disability in Children: Maternal Mental Illness vs Obstetric Complications
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- FDA Approves Powerful New Opioid Despite Criticisms
- These Tools May Help Providers and Policymakers to Address the Opioid Crisis